Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer
NCT05127382
·
clinicaltrials.gov ↗
UNKNOWN
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer Non-small Cell Stage IV
Sponsor
Hellenic Cooperative Oncology Group